A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.
Epistemonikos ID: 6a622ef57639a529417345eb04f5719c70b6e64e
First added on: Feb 15, 2022